课题基金 / 基金详情

项目摘要

项目成果

JOHN S. LAZO的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract High-content screening employs an imaging-based platform, which combines the efficacy and speed of high-throughput automation and the power of light microscopy, especially fluorescence microscopy, to simultaneously capture both functional and morphometric information from a large number of samples of cells or organisms following perturbation, such as drug treatment or genetic alteration. High content analysis permits a much more comprehensive quantitative assessment of drug and gene effects than population-based methods, because multiple kinetic and spatial readouts can be simultaneously interrogated in individual cells. This application seeks to fill the gap between a strong demand for high-content screening and the limited capability the University of Virginia can currently offer. The proposed instrument is a PerkinElmer Operetta CLS, a high-content imaging system capable of bright-field, phase-contrast, and wide-field and spinning-disc confocal fluorescence imaging. The acquisition will immediately benefit a wide range of biomedical research projects covering infectious diseases such as influenza, Ebola, cardiovascular disease, obesity, cancer, peripheral and central neurodegeneration. With the Operetta CLS, multiple parameters can be captured simultaneously for evaluation of tool or drug candidates against known targets as well as for uncovering unknown new targets in the exploration of a biological problem. Added benefit is unbiased image acquisition and powerful data analysis. The Operetta CLS is positioned to critical new research tool to facilitate our extensive basic or clinical research programs, which are attempting to understand and find treatments for human diseases.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1002/psp4.12599
发表时间: 2021-04
期刊: CPT: pharmacometrics & systems pharmacology
影响因子: --
作者: [Zeigler AC, Chandrabhatla AS, Christiansen SL, Nelson AR, Holmes JW, Saucerman JJ]
通讯作者: Saucerman JJ
Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches.
使用合成致死方法缩短确定具有挑战性的肿瘤治疗靶点和药物组合的时间。
DOI: 10.12688/f1000research.13679.1
发表时间: 2018
期刊: F1000Research
影响因子: --
作者: [Lazo,JohnS]
通讯作者: Lazo,JohnS
DOI: 10.1016/j.slasd.2022.10.002
发表时间: 2023-09
期刊: SLAS DISCOVERY
影响因子: 3.1
作者: [Sharlow, Elizabeth R., Llaneza, Danielle C., Grever, William E., Mingledorff, Garnett A., Mendelson, Anna J., Bloom, George S., Lazo, John S.]
通讯作者: Lazo, John S.
A PTP4A3 inhibitor for SARS-CoV-2-mediated acute lung injury
  • 批准号:
    10632154
  • 项目类别:
  • 资助金额:
    $0.65万
  • 财政年份:
    2022
  • 负责人:
    JOHN S. LAZO
  • 依托单位:
A PTP4A3 inhibitor for SARS-CoV-2-mediated acute lung injury
  • 批准号:
    10330408
  • 项目类别:
  • 资助金额:
    $25.22万
  • 财政年份:
    2021
  • 负责人:
    JOHN S. LAZO
  • 依托单位:
A PTP4A3 inhibitor for SARS-CoV-2-mediated acute lung injury
  • 批准号:
    10540550
  • 项目类别:
  • 资助金额:
    $5.5万
  • 财政年份:
    2021
  • 负责人:
    JOHN S. LAZO
  • 依托单位:
Developing small molecule PTP4A3 inhibitors for ovarian cancer
  • 批准号:
    9769367
  • 项目类别:
  • 资助金额:
    $28.93万
  • 财政年份:
    2019
  • 负责人:
    JOHN S. LAZO
  • 依托单位:
海外基金